InnoCan Pharma Corporation INNO
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -18.39% | -17.02% | -9.60% | -6.58% | 18.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -18.39% | -17.02% | -9.60% | -6.58% | 18.20% |
| Cost of Revenue | -32.56% | -18.62% | -17.51% | 8.84% | 36.66% |
| Gross Profit | -16.54% | -16.83% | -8.61% | -8.27% | 16.15% |
| SG&A Expenses | -0.67% | -4.86% | -6.30% | -5.83% | 5.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.44% | -7.33% | -9.18% | -6.22% | 4.94% |
| Operating Income | -1,179.87% | -657.27% | -0.64% | -2.45% | 111.44% |
| Income Before Tax | -239.11% | -135.45% | -90.75% | -550.60% | 128.66% |
| Income Tax Expenses | -104.48% | -81.14% | -63.93% | -45.01% | 1.19% |
| Earnings from Continuing Operations | -170.45% | -203.63% | -30.15% | -122.18% | 90.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 90.14% | 67.99% | 50.19% | 37.92% | -4.02% |
| Net Income | 39.21% | -133.28% | 38.71% | -24.20% | 63.69% |
| EBIT | -1,179.87% | -657.27% | -0.64% | -2.45% | 111.44% |
| EBITDA | -1,065.34% | -609.20% | -0.08% | -2.62% | 112.83% |
| EPS Basic | 40.37% | -130.90% | 43.46% | -14.39% | 66.98% |
| Normalized Basic EPS | -124.18% | -829.43% | 49.63% | 8.76% | 85.83% |
| EPS Diluted | 40.37% | -130.90% | 43.46% | -14.39% | 66.98% |
| Normalized Diluted EPS | -124.18% | -829.43% | 49.63% | 8.76% | 85.83% |
| Average Basic Shares Outstanding | 1.50% | 2.51% | 4.21% | 5.71% | 7.01% |
| Average Diluted Shares Outstanding | 1.50% | 2.51% | 4.21% | 5.71% | 7.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |